Abstract:To investigate whether tumor cell lysate-pulsed (TP) dendritic cells (DCs) induce cytotoxic T lymphocyte (CTL) activity against colon cancer in vitro and in vivo . Hematopoietic progenitor cells were magnetically isolated from BALB/c mice bone marrow cells. These cells were cultured with cytokines GM-CSF, IL-4, and TNFα to induce their maturation. They were analyzed by morphological observation and phenotype analysis. DCs were pulsed with tumor cell lysate obtained by rapid freezing and thawing at a 1:3 DC:tumor cell ratio. CTL activity and interferon gamma (IFNγ) secretion was evaluated ex vivo. In order to determine whether or not vaccination with CT26 TP DCs induce the therapeutic potential in the established colon tumor model, CT26 colon tumor cells were implanted subcutaneously (s.c.) in the midflank of naïve BALB/c mice. Tumor-bearing mice were injected with vaccination with CT26 TP DCs on days 3 and 10. Tumor growth was assessed every 2–3 days. Finally, CTL activity and IFNγ secretion were evaluated in immunized mice. Hematopoietic progenitor cells from mice bone marrow cells cultured with cytokines for 8 days showed the character of typical mature DCs. Morphologically, these cells were large with oval or irregularly shaped nuclei and with many small dendrites. Phenotypically, FACS analysis showed that they expressed high levels of MHC II, CD11b, CD80, and CD86 antigen, and were negative for CD8α. However, immature DCs cultured with cytokines for 5 days did not have typical DCs phenotypic markers. Ex vivo primed T cells with CT26 TP DCs were able to induce effective CTL activity against CT26 tumor cells, but not B16 tumor cells ( E : T = 100:1, 60.36 ± 7.11% specific lysis in CT26 group vs. 17.36 ± 4.10% specific lysis in B16 group), and produced higher levels of IFNγ when stimulated with CT26 tumor cells but not when stimulated with B16 tumor cells (1210.33 ± 72.15 pg/ml in CT26 group vs. 182.25 ± 25.51 pg/ml in B16 group, P < 0.01). Vaccination with CT26 TP DCs could induce anti-tumor immunity against CT26 colon tumor in murine therapeutic models (tumor volume on day 19: CT26 TP DCs 342 ± 55 mm 3 vs. the other control groups, P < 0.05). In addition, all splenic CD3 + T cells obtained from mice vaccinated with CT26 TP DCs produced high levels of IFNγ and shown specific cytotoxic activity against CT26 tumor cells, but no cytotoxic activity when stimulated with B16 tumor cells. Tumor cell lysate-pulsed DCs can induce tumor-specific CTL activity against colon cancer in vitro and in vivo .

[Autologous lung cancer tissues derived gp96-peptide complex/dendritic cell vaccine induces the cytotoxic T cell response in vitro].

Leukemia: Derived Heat Shock Protein Gp96-Peptide Complex Contribution to T Cell and Dendritic Cell Activation

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Anti-tumor Immunity with Dendritic Cells ( DC) Vaccine Modified by IL-18

Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation.

Potent Antitumor Effect Elicited by Gp96-Peptide Complexes Pulsed by Dendritic Cell on Mice of H22 Liver Cancer

Antitumor Effect of Dendritic Cell Modified by Gp96-peptide Complex

The anti-leukemia effect of heat shock protein-peptide complex-96

[The Killing Effect of Cytotoxic T Lymphocytes on Esophageal Adenocarcinoma Cells Mediated by Gp96-Peptide Complexes].

Effect of gp96 polypeptide complex dendritic cell vaccine on Th1/ Th2 balance

Dendritic cells loaded with apoptotic tumor cells in the treatment of lung cancer

Cytotoxic Effects of CTLs Activated by DCs to Kill Autologous Breast Cancer Cells

Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100

[Killing Activity of Cytotoxic T Lymphocytes Stimulated by Dendritic Cell Vaccine Loaded with Autologous Cervical Cancer Antigen].

Bone Marrow-Derived Dendritic Cells Pulsed with Tumor Lysates Induce Anti-Tumor Immunity Against Gastric Cancer Ex Vivo

Research of dendritic cells pulsed with PSA peptide inducing specific CTL in vitro

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

Antitumor Efficacy of a Photodynamic Therapy-Generated Dendritic Cell Glioma Vaccine

Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo

[Assessment of Lymphocytic Function in Vitro Stimulated by Specific Tumor Polypeptide Combined with Dendritic Cells].

Eliciting Cytotoxic T Lymphocytes Against Human Laryngeal Cancer-Derived Antigens: Evaluation of Dendritic Cells Pulsed with a Heat-Treated Tumor Lysate and Other Antigen-Loading Strategies for Dendritic-Cell-based Vaccination